Hu23F2G monoclonal antibody: ICOS began a Phase II trial

ICOS Corp. (ICOS), Seattle, Wash. Product: Hu23F2G monoclonal antibody Indication: Trauma-induced hemorrhagic shock Status: ICOS began a Phase II trial of its Hu23F2G monoclonal antibody in patients w...